AbbVie Inc

ABBV

220.700USD

+9.060+4.28%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

38 / 177

Overall Ranking

126 / 4730

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 31 analysts

Buy

Current Rating

217.756

Target Price

+2.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 263.76%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 263.76%.

Overvalued

The company’s latest PE is 100.53, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.32B shares, increasing 0.78% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 176.50M shares of this stock.

The company's current financial score is 7.46, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 13.34B, representing a year-over-year increase of 8.39%, while its net profit experienced a year-over-year increase of 6.11%.

Score

Industry at a Glance

Previous score

7.46

Change

0



Financials

6.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.60

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.83

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.43

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 98.83, which is -33.75% below the recent high of 65.47 and 65.57% above the recent low of 34.02.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/177

No Data

The company’s current earnings forecast score is 7.79, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for AbbVie Inc is 215.00, with a high of 255.00 and a low of 170.00.

Score

Industry at a Glance

Previous score

7.81

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.43, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 217.80 and the support level at 192.97, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.01

Change

0.06

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-10

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 74.93%, representing a quarter-over-quarter increase of 0.05%. The largest institutional shareholder is The Vanguard, holding a total of 176.50M shares, representing 9.99% of shares outstanding, with 2.47% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

177.27M

+2.38%

BlackRock Institutional Trust Company, N.A.

91.03M

+1.06%

State Street Global Advisors (US)

79.96M

+0.43%

Geode Capital Management, L.L.C.

38.25M

+2.98%

JP Morgan Asset Management

35.61M

+5.02%

Charles Schwab Investment Management, Inc.

25.27M

-7.91%

Capital Research Global Investors

33.51M

-1.40%

Morgan Stanley Smith Barney LLC

23.25M

+2.52%

Norges Bank Investment Management (NBIM)

25.10M

+11.64%

Fidelity Management & Research Company LLC

21.43M

+26.15%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.93, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

AbbVie Inc

ABBV

6.71 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BridgeBio Pharma Inc

BBIO

7.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Biogen Inc

BIIB

7.29 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.